Mitigating disruptions, and scalability of radiation oncology physics work during the COVID-19 pandemic.
Betacoronavirus
COVID-19
Coronavirus Infections
/ epidemiology
Health Facilities
/ standards
Health Personnel
Health Physics
/ organization & administration
Humans
Pandemics
Pneumonia, Viral
/ epidemiology
Practice Guidelines as Topic
/ standards
Quality Assurance, Health Care
Radiation Oncology
/ organization & administration
SARS-CoV-2
United States
/ epidemiology
COVID-19
contingency plan
coronavirus
medical physics
pandemic
radiation oncology
Journal
Journal of applied clinical medical physics
ISSN: 1526-9914
Titre abrégé: J Appl Clin Med Phys
Pays: United States
ID NLM: 101089176
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
12
04
2020
revised:
12
04
2020
accepted:
13
04
2020
pubmed:
21
5
2020
medline:
7
8
2020
entrez:
21
5
2020
Statut:
ppublish
Résumé
The COVID-19 pandemic has led to disorder in work and livelihood of a majority of the modern world. In this work, we review its major impacts on procedures and workflow of clinical physics tasks, and suggest alternate pathways to avoid major disruption or discontinuity of physics tasks in the context of small, medium, and large radiation oncology clinics. We also evaluate scalability of medical physics under the stress of "social distancing". Three models of facilities characterized by the number of clinical physicists, daily patient throughput, and equipment were identified for this purpose. For identical objectives of continuity of clinical operations, with constraints such as social distancing and unavailability of staff due to system strain, however with the possibility of remote operations, the performance of these models was investigated. General clinical tasks requiring on-site personnel presence or otherwise were evaluated to determine the scalability of the three models at this point in the course of disease spread within their surroundings. The clinical physics tasks within three models could be divided into two categories. The former, which requires individual presence, include safety-sensitive radiation delivery, high dose per fraction treatments, brachytherapy procedures, fulfilling state and nuclear regulatory commission's requirements, etc. The latter, which can be handled through remote means, include dose planning, physics plan review and supervision of quality assurance, general troubleshooting, etc. CONCLUSION: At the current level of disease in the United States, all three models have sustained major system stress in continuing reduced operation. However, the small clinic model may not perform if either the current level of infections is maintained for long or staff becomes unavailable due to health issues. With abundance, and diversity of innovative resources, medium and large clinic models can sustain further for physics-related radiotherapy services.
Identifiants
pubmed: 32432389
doi: 10.1002/acm2.12896
pmc: PMC7285927
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
187-195Informations de copyright
© 2020 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals, Inc. on behalf of American Association of Physicists in Medicine.
Références
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
J Appl Clin Med Phys. 2015 May 08;16(3):5232
pubmed: 26103483
Adv Radiat Oncol. 2020 Apr 06;5(4):534-537
pubmed: 32363245
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Radiother Oncol. 2020 Jul;148:203-210
pubmed: 32342870
Diagn Interv Radiol. 2020 May;26(3):200-203
pubmed: 32209526
Adv Radiat Oncol. 2020 Apr 09;5(4):666-672
pubmed: 32292844
Radiother Oncol. 2020 Jul;148:213-215
pubmed: 32342861
J Appl Clin Med Phys. 2018 Nov;19(6):332-335
pubmed: 30328675
Adv Radiat Oncol. 2020 Mar 27;5(4):538-543
pubmed: 32292841
J Appl Clin Med Phys. 2018 Nov;19(6):11-25
pubmed: 30338913
Int J Radiat Oncol Biol Phys. 2020 Jul 15;107(4):618-627
pubmed: 32302681
Adv Radiat Oncol. 2020 Apr 08;5(4):589-594
pubmed: 32363243
Adv Radiat Oncol. 2020 Mar 20;5(4):527-530
pubmed: 32292837
Nat Med. 2020 Apr;26(4):506-510
pubmed: 32284616
Int J Radiat Oncol Biol Phys. 2020 Jul 1;107(3):597-599
pubmed: 32199941
Nat Med. 2020 Apr;26(4):450-452
pubmed: 32284615
Med Phys. 2016 Jul;43(7):4209
pubmed: 27370140
Adv Radiat Oncol. 2020 Apr 01;5(4):560-566
pubmed: 32292840
Adv Radiat Oncol. 2020 Mar 31;5(4):577-581
pubmed: 32363249
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
Adv Radiat Oncol. 2020 Mar 27;5(4):544-547
pubmed: 32313845
Med Phys. 2017 Oct;44(10):e391-e429
pubmed: 28688159
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Adv Radiat Oncol. 2020 Mar 27;5(4):531-533
pubmed: 32775770
Adv Radiat Oncol. 2020 Apr 01;5(4):582-588
pubmed: 32292842
Adv Radiat Oncol. 2020 Apr 01;5(4):573-574
pubmed: 32292838